{'52WeekChange': -0.12422365,
 'SandP52WeekChange': None,
 'address1': '95 Pitt Street',
 'address2': 'Level 12',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.44,
 'askSize': 3100,
 'averageDailyVolume10Day': 8334300,
 'averageVolume': 1382160,
 'averageVolume10days': 8334300,
 'beta': 1.168023,
 'beta3Year': None,
 'bid': 1.38,
 'bidSize': 900,
 'bookValue': 0.8,
 'category': None,
 'circulatingSupply': None,
 'city': 'Sydney',
 'companyOfficers': [],
 'country': 'Australia',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.44,
 'dayLow': 1.37,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 55986856,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '61 2 8569 1880',
 'fiftyDayAverage': 1.1668571,
 'fiftyTwoWeekHigh': 3.1,
 'fiftyTwoWeekLow': 0.53,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 36372405,
 'forwardEps': -0.27,
 'forwardPE': -5.3333335,
 'fromCurrency': None,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.01811,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1561852800,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/immutep.com',
 'longBusinessSummary': 'Immutep Limited, a biotechnology company, engages in '
                        'the research, development, and commercialization of '
                        'biological products. The company develops '
                        'immunotherapeutic products for the treatment of '
                        'cancer and autoimmune diseases. Its therapeutics are '
                        'based on the lymphocyte activation gene-3 (LAG-3) Ig '
                        'fusion protein, a cell surface molecule that plays a '
                        "role in regulating T cells. The company's lead "
                        'product candidate is eftilagimod alpha (efti), an '
                        'antigen presenting cell activator, which is in a '
                        'Phase IIb clinical trial as a chemoimmunotherapy for '
                        'metastatic breast cancer. Its other products include '
                        'TACTI-002, a combination of efti with KEYTRUDA that '
                        'is in a Phase II clinical trial for solid tumors; '
                        'INSIGHT-004, a human anti-PD-L1 antibody, which is in '
                        'a Phase I clinical trial to evaluate a combination of '
                        'efti with avelumab; and TACTI-mel that is in a Phase '
                        'I clinical trial for metastatic melanoma. The company '
                        'also develops IMP761 for autoimmune disease. It has '
                        'operations in Europe, Australia, and the United '
                        'States. Immutep Limited has a clinical trial '
                        'collaboration and supply agreements with Merck KGaA, '
                        'Darmstadt, Germany, and Pfizer Inc.; and partnerships '
                        'with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC '
                        'Pharma. The company was formerly known as Prima '
                        'BioMed Ltd and changed its name to Immutep Limited in '
                        'November 2017. Immutep Limited is headquartered in '
                        'Sydney, Australia.',
 'longName': 'Immutep Limited',
 'market': 'us_market',
 'marketCap': 56689636,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_6701589',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1625011200,
 'open': 1.38,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '61 2 8315 7003',
 'previousClose': 1.41,
 'priceHint': 4,
 'priceToBook': 1.8000001,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -1.2055,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.44,
 'regularMarketDayLow': 1.37,
 'regularMarketOpen': 1.38,
 'regularMarketPreviousClose': 1.41,
 'regularMarketPrice': 1.38,
 'regularMarketVolume': 534888,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 38879800,
 'sharesPercentSharesOut': 0.002,
 'sharesShort': 170322,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 245372,
 'shortName': 'Immutep Limited',
 'shortPercentOfFloat': None,
 'shortRatio': 0.3,
 'startDate': None,
 'state': 'NSW',
 'strikePrice': None,
 'symbol': 'IMMP',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.4,
 'twoHundredDayAverage': 1.5176978,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'c6d72204-94f0-3b31-acc4-15ee84e34cde',
 'volume': 534888,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.immutep.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '2000'}